New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
09:29 EDTABT, RIGLRigel Pharmaceuticals price target lowered to $8 from $15 at Roth Capital
Roth Capital lowered its target on Rigel after the company's rheumatoid arthritis treatment fostamatinib did not demonstrate equivalence versus Abbott's (ABT) Humira in a Phase II test. The firm reduced its estimates for fostamatinib but maintains a Buy rating on the stock based on valuation.
News For RIGL;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:32 EDTRIGLRigel Pharmaceuticals announces retirement of Chairman and CEO James Gower
Rigel Pharmaceuticals announced James Gower is retiring from the board and from his positions as Chairman and CEO, and Raul Rodriguez, most recently serving as the company's President and COO, will assume the position of chief executive officer and join the board. Gary Lyons, a member of Rigel's board since 2005, will become chairman. Gower is expected to remain an employee until the end of the year and, thereafter will be a consultant to the company providing advice on strategy, business development and other matters.
November 17, 2014
08:16 EDTABTZoetis to purchase assets of Abbott Animal Health for about $255M
Subscribe for More Information
08:15 EDTABTZoetis to purchase assets of Abbott Animal Health for about $255M

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use